XML 42 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Acquisitions, Strategic Transaction and Integration Expenses Business Combination (Tables)
 12 Months Ended
Dec. 31, 2018
Business Acquisition [Line Items]  
Business Acquisition, Pro Forma Information [Table Text Block]
(In millions)
 
Revenue
 
Earnings
Actual from 2/3/2017 - 12/31/2017(3)
 
$
1,062

 
*
2017 supplemental pro forma from 1/1/2017 - 12/31/2017(1)(2)
 
$
1,373

 
$
91

2016 supplemental pro forma from 1/1/2016 - 12/31/2016(1)(2)
 
$
1,418

 
$
99

______________________________
* Impracticable to calculate.
(1) 2017 supplemental pro forma earnings were adjusted to exclude $66.3 million of nonrecurring expense related to the fair value adjustment to acquisition-date inventory, $59.2 million of acquisition and integration-related costs and $70.9 million in bargain purchase gain. 2016 supplemental pro forma earnings were adjusted to include these charges. These amounts were updated in 2018 from the 2017 disclosed amounts to incorporate information not previously available.
(2) Unaudited.
(3) Amount represents activity of HIS from the date of the acquisition.
Hospira [Member]  
Business Acquisition [Line Items]  
Schedule of Business Acquisitions, by Acquisition [Table Text Block]
The following table summarizes the final purchase price and the final allocation of the purchase price related to the assets and liabilities purchased (in thousands, except per share data):

Cash consideration for acquired assets
 
$
180,785

Fair value of Seller Note
 
75,000

Fair value of contingent consideration payable to Pfizer (long-term)
 
19,000

 
 
 
Issuance of ICU Medical, Inc. common shares:
 
 
Number of shares issued to Pfizer
 
3,200

Price per share (ICU's trading closing share price on the Closing Date)
 
$
140.75

Market price of ICU shares issued to Pfizer
 
$
450,400

Less: Discount due to lack of marketability of 8.3%
 
(37,261
)
Equity portion of purchase price
 
413,139

Total Consideration
 
$
687,924

 
 
 
Purchase Price Allocation:
 
 
Cash and cash equivalents
 
$
31,082

Trade receivables
 
362

Inventories
 
417,622

Prepaid expenses and other assets
 
13,911

Property, plant and equipment
 
288,134

Intangible assets(1)
 
131,000

Other assets
 
29,270

Accounts payable
 
(12,381
)
Accrued liabilities
 
(47,936
)
Long-term liabilities(2)
 
(67,170
)
Total identifiable net assets acquired
 
$
783,894

Deferred tax, net
 
(25,080
)
Estimated Gain on Bargain Purchase
 
(70,890
)
Estimated Purchase Consideration
 
$
687,924

______________________________

(1) Identifiable intangible assets includes $48 million of customer relationships, $44 million of developed technology - pumps and dedicated sets, $34 million of developed technology - consumables, and $5 million of in-process research and development ("IPR&D"). The weighted amortization period for the total identifiable assets is approximately nine years, for customer relationships the weighted amortization period is eight years, for the developed technology - pumps and dedicated sets the weighted amortization period is ten years and for the developed technology - consumables the weighted amortization period is twelve years. The IPR&D is non-amortizing until the associated research and development efforts are complete.

(2) Long-term liabilities primarily consisted of contract liabilities, product liabilities and long-term employee benefits.